Responses
Interstitial lung disease
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
Compose a Response to This Article
Other responses
No responses have been published for this article.